Caseware UK (AP4) 2022.0.179 2022.0.179 2023-03-312023-03-31falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2022-04-01falseOther human health activities3422true 12074511 2022-04-01 2023-03-31 12074511 2021-04-01 2022-03-31 12074511 2023-03-31 12074511 2022-03-31 12074511 2021-04-01 12074511 c:Director7 2022-04-01 2023-03-31 12074511 d:OfficeEquipment 2022-04-01 2023-03-31 12074511 d:OfficeEquipment 2023-03-31 12074511 d:OfficeEquipment 2022-03-31 12074511 d:OfficeEquipment d:OwnedOrFreeholdAssets 2022-04-01 2023-03-31 12074511 d:CurrentFinancialInstruments 2023-03-31 12074511 d:CurrentFinancialInstruments 2022-03-31 12074511 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 12074511 d:CurrentFinancialInstruments d:WithinOneYear 2022-03-31 12074511 d:ShareCapital 2022-04-01 2023-03-31 12074511 d:ShareCapital 2023-03-31 12074511 d:ShareCapital 2022-03-31 12074511 d:ShareCapital 2021-04-01 12074511 d:RetainedEarningsAccumulatedLosses 2022-04-01 2023-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2023-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2021-04-01 2022-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2022-03-31 12074511 d:RetainedEarningsAccumulatedLosses 2021-04-01 12074511 d:AcceleratedTaxDepreciationDeferredTax 2023-03-31 12074511 d:AcceleratedTaxDepreciationDeferredTax 2022-03-31 12074511 c:OrdinaryShareClass1 2022-04-01 2023-03-31 12074511 c:OrdinaryShareClass1 2023-03-31 12074511 c:OrdinaryShareClass1 2022-03-31 12074511 c:OrdinaryShareClass2 2022-04-01 2023-03-31 12074511 c:OrdinaryShareClass2 2023-03-31 12074511 c:OrdinaryShareClass3 2022-04-01 2023-03-31 12074511 c:OrdinaryShareClass3 2023-03-31 12074511 c:FRS102 2022-04-01 2023-03-31 12074511 c:AuditExempt-NoAccountantsReport 2022-04-01 2023-03-31 12074511 c:FullAccounts 2022-04-01 2023-03-31 12074511 c:PrivateLimitedCompanyLtd 2022-04-01 2023-03-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 12074511










EVEXIA HEALTH LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2023

 
EVEXIA HEALTH LTD
REGISTERED NUMBER: 12074511

BALANCE SHEET
AS AT 31 MARCH 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
2,211
1,219

Current assets
  

Debtors: amounts falling due within one year
 5 
130,601
426,827

Cash at bank and in hand
 6 
709,697
345,556

  
840,298
772,383

Creditors: amounts falling due within one year
 7 
(364,207)
(474,273)

Net current assets
  
 
 
476,091
 
 
298,110

Total assets less current liabilities
  
478,302
299,329

Provisions for liabilities
  

Deferred tax
 8 
(553)
(305)

  
 
 
(553)
 
 
(305)

Net assets
  
477,749
299,024


Capital and reserves
  

Called up share capital 
 9 
2,080
2

Profit and loss account
  
475,669
299,022

  
477,749
299,024


Page 1

 
EVEXIA HEALTH LTD
REGISTERED NUMBER: 12074511
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 






................................................
Dr K Singh
Director

Date: 24 November 2023

The notes on pages 4 to 9 form part of these financial statements.

Page 2

 
EVEXIA HEALTH LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2023


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 April 2021
2
178,018
178,020


Comprehensive income for the year

Profit for the year
-
121,004
121,004



At 1 April 2022
2
299,022
299,024


Comprehensive income for the year

Profit for the year
-
176,647
176,647


Contributions by and distributions to owners

Shares issued during the year
2,078
-
2,078


At 31 March 2023
2,080
475,669
477,749


The notes on pages 4 to 9 form part of these financial statements.

Page 3

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

1.


General information

Evexia Health Ltd ("the Company") is a private company limited by shares incorporated in England and Wales, registered number 12074511. The Company is registered at 2A Malzeard Road, Luton, LU3 1BD.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 4

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)

 
2.3

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of Comprehensive Income in the same period as the related expenditure.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 5

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)


2.6
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment
-
25%
straight-line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.10

Provisions for liabilities

Provisions are made where an event has taken place that gives the Company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to profit or loss in the year that the Company becomes aware of the obligation, and are measured at the best estimate at the balance sheet date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Balance Sheet.

 
2.11

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Page 6

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

2.Accounting policies (continued)


2.11
Financial instruments (continued)

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Comprehensive Income.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.


3.


Employees

The average monthly number of employees, including directors, during the year was 34 (2022 - 22).


4.


Tangible fixed assets





Office equipment

£



Cost or valuation


At 1 April 2022
1,913


Additions
1,592



At 31 March 2023

3,505



Depreciation


At 1 April 2022
694


Charge for the year on owned assets
600



At 31 March 2023

1,294



Net book value



At 31 March 2023
2,211



At 31 March 2022
1,219

Page 7

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

5.


Debtors

2023
2022
£
£


Trade debtors
125,338
416,362

Called up share capital not paid
1
2

Prepayments and accrued income
5,262
10,463

130,601
426,827



6.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
709,697
345,556



7.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
51,446
59,718

Corporation tax
41,398
26,568

Other taxation and social security
31,275
14,267

Other creditors
12,456
-

Accruals and deferred income
227,632
373,720

364,207
474,273


Page 8

 
EVEXIA HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2023

8.


Deferred taxation




2023


£






At beginning of year
(305)


Charged to profit or loss
(248)



At end of year
(553)

The provision for deferred taxation is made up as follows:

2023
2022
£
£


Accelerated capital allowances
(553)
(305)


9.


Share capital

2023
2022
£
£
Allotted, called up and fully paid



22 (2022 - 2) Ordinary B shares of £1.00 each
22
2
205,745 (2022 - ) Ordinary A shares of £0.01 each
2,057
-
1 (2022 - ) Ordinary C share of £1.00
1
-

2,080

2


Each A Share entitles the holder to receive a dividend and to participate in a distribution, including a distribution arising from a winding up of the company. A Shares shall not entitle the holder to a vote. A Shares may be redeemed at the option of the company.
Each B Share entitles the holder to one vote in any circumstances, but shall not entitle the holder to receive a dividend or distribution. B Shares may be redeemed at the option of the company.
C Shares shall not entitle the holder to receive a dividend or distribution. C Shares shall not be redeemable.

 
Page 9